OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Virginia Solitano, Paola Facheris, Magnus Petersen, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103504-103504
Open Access | Times Cited: 7
Virginia Solitano, Paola Facheris, Magnus Petersen, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103504-103504
Open Access | Times Cited: 7
Showing 7 citing articles:
Therapeutic Inhibition of the JAK-STAT pathway in the treatment of Inflammatory Bowel Disease.
Zihan Chen, Ping Jiang, Dan Su, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 1-15
Closed Access | Times Cited: 4
Zihan Chen, Ping Jiang, Dan Su, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 1-15
Closed Access | Times Cited: 4
Causes of Mortality in Intensive Care Units for Patients with Chronic Inflammatory Diseases from the French National Health Data System
Yannis Hamidou, Jean-Marc Sobhy-Danial, Thibault Balcaen, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 2000-2000
Open Access
Yannis Hamidou, Jean-Marc Sobhy-Danial, Thibault Balcaen, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 2000-2000
Open Access
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy
Marino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3929-3929
Open Access | Times Cited: 2
Marino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3929-3929
Open Access | Times Cited: 2
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
Jeffrey A. Lowell, G.V.R.K. Sharma, Arun Swaminath, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 1
Jeffrey A. Lowell, G.V.R.K. Sharma, Arun Swaminath, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 1
Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management
Antonio M.� Caballero-Mateos, Guillermo A. Cañadas‐De la Fuente
World Journal of Gastroenterology (2024) Vol. 30, Iss. 35, pp. 3942-3953
Closed Access | Times Cited: 1
Antonio M.� Caballero-Mateos, Guillermo A. Cañadas‐De la Fuente
World Journal of Gastroenterology (2024) Vol. 30, Iss. 35, pp. 3942-3953
Closed Access | Times Cited: 1
Raising the bar in ulcerative colitis management
Fabrizio Fanizzi, Mariangela Allocca, Gionata Fiorino, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Fabrizio Fanizzi, Mariangela Allocca, Gionata Fiorino, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
